Maximum time between cardiac cycles in atrial fibrillation for assessing the risk of arterial thromboembolism

Maximum time between cardiac cycles in atrial fibrillation for assessing the risk of arterial thromboembolism

Aim. To assess the development of thromboembolic events in different types of atrial fibrillation (AF), which differ in the maximum time between cardiac cycles.Material and methods. The main group included 80 patients with permanent AF, while the control one — 88 people without AF. The following inv...

Full description

Bibliographic Details
Main Authors:	O. A. Germanova, A. V. Germanov, Yu. V. Shchukin
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2022-08-01
Series:	Российский кардиологический журнал
Subjects:	atrial fibrillation thromboembolic events arterial hemodynamics
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/5007

Similar Items

Differential Presentations of Arterial Thromboembolic Events Between Venous Thromboembolism and Atrial Fibrillation Patients
by: Yu-Sheng Lin, et al.
Published: (2021-12-01)

Optimal choice of prophylactic anticoagulant therapy for nonvalvular atrial fibrillation in the context of COVID-19 pandemic
by: A. S. Polyakov, et al.
Published: (2021-09-01)

Atrial Fibrillation and Cryptogenic Thromboembolic Events
by: Benhur Davi Henz, et al.

Age-dependent risk for thromboembolism in atrial fibrillation: The Fushimi AF registry
by: Masahiro Esato, et al.
Published: (2022-08-01)

Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub‐Analysis From the PREFER in AF (PREvention oF Thromboembolic Events–European Registry in Atrial Fibrillation)
by: Giuseppe Patti, et al.
Published: (2017-07-01)

NOVEL ANTICOAGULANTS FOR THROMBOEMBOLIC COMPLICATIONS PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
by: D. A. Itkin, et al.
Published: (2015-02-01)

Risk of Thromboembolism in Non-Valvular Atrial Fibrillation With or Without Clinical Hyperthyroidism
by: Yu-Sheng Lin, et al.
Published: (2021-06-01)

Atrial fibrillation and the risk of 30‐day incident thromboembolic events, and mortality in adults ≥ 50 years with COVID‐19
by: Stephanie L. Harrison, et al.
Published: (2021-02-01)

Estimating the cost-effectiveness of treatment for prevention of thromboembolic events in at-risk adults with non-valvular atrial fibrillation
by: Marco Bellone, et al.
Published: (2018-02-01)

Atrial fibrillation in hypertrophic cardiomyopathy – A contemporary mini-review
by: Stylianos Dragasis, et al.
Published: (2022-09-01)

Contrast enhanced transesophageal echocardiography in patients with atrial fibrillation referred to electrical cardioversion improves atrial thrombus detection and may reduce associated thromboembolic events
by: Jung Philip H, et al.
Published: (2013-01-01)

Ibrutinib in patients with atrial fibrillation – the challenge of thromboembolic prophylaxis
by: Ciuculete Denisa-Corina, et al.
Published: (2021-09-01)

Thromboembolic risks associated with paroxysmal and persistent atrial fibrillation in Asian patients: a report from the Chinese atrial fibrillation registry
by: Ying Wang, et al.
Published: (2019-11-01)

Assessment of Thromboembolism After the Cox-Maze Procedure for Chronic Atrial Fibrillation Secondary to Mitral Valve Lesion
by: Kalil Renato A. K., et al.
Published: (2002-01-01)

Prevalence, predictors and management of left atrial appendage thrombogenic milieu in atrial fibrillation with low thromboembolic risk
by: Yu Qiao, et al.
Published: (2023-03-01)

Features of Thromboembolic and Hemorrhagic Complications in Planned Surgical Interventions in Patients with Atrial Fibrillation
by: L. N. Uddin, et al.
Published: (2019-07-01)

Pilot study of peripheral blood chemokines as biomarkers for atrial fibrillation-related thromboembolism and bleeding in elderly patients
by: Meihui Tai, et al.
Published: (2022-09-01)

Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors
by: Mahito Ozawa, MD, et al.
Published: (2009-01-01)

Left Atrial Diameter in the Prediction of Thromboembolic Event and Death in Atrial Fibrillation
by: Rungroj Krittayaphong, et al.
Published: (2022-03-01)

Relationship between coarse F waves and thromboembolic events in patients with permanent atrial fibrillation
by: Yahya Kemal İçen, et al.
Published: (2020-12-01)

Efficacy and safety of left atrial appendage closure in patients with atrial fibrillation and high thromboembolic and bleeding risk
by: D. V. Pevzner, et al.
Published: (2022-09-01)

Secondary prevention of thromboembolic complications in patients with nonvalvular atrial fibrillation – clinical practice in relation to guidelines
by: Bernadetta Bielecka, et al.
Published: (2023-06-01)

RISK OF THROMBOEMBOLIC COMPLICATIONS AND ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT AND RECURRENT ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE
by: I. V. Grajfer, et al.
Published: (2015-12-01)

Risk of Venous Thromboembolic Complications in Patients with Atrial Fibrillation: a Systematic Review and Meta-analysis
by: A. A. Sokolova, et al.
Published: (2022-07-01)

Atrial fibrillation, venous thromboembolism, ischemic stroke, and all‐cause mortality: The Tromsø study
by: Erin Mathiesen Hald, et al.
Published: (2020-08-01)

Laboratory predictors of clinical outcomes in patients with atrial fibrillation
by: A. A. Sokolova, et al.
Published: (2021-05-01)

MODERN APPROACHES TO ANTICOAGULANT THERAPY DURING CATHETER ABLATION TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION
by: E. A. Belikov, et al.
Published: (2015-09-01)

Gender Differences in Atrial Fibrillation: From the Thromboembolic Risk to the Anticoagulant Treatment Response
by: Anna Rago, et al.
Published: (2023-01-01)

Gaps in guideline-recommended anticoagulation in patients with atrial fibrillation and elevated thromboembolic risk within an integrated healthcare delivery system
by: Sushmita Malik, et al.
Published: (2023-11-01)

A new method of left atrial appendage occlusion for the prevention of thromboembolic complications in patients with atrial fibrillation during coronary artery bypass grafting
by: Yu. Yu. Vecherskiy, et al.
Published: (2020-09-01)

Arterial stiffness and atrial fibrillation: A review
by: Joao Gabriel Batista Lage, et al.
Published: (2022-04-01)

Impact of Blood Pressure Control on Thromboembolism and Major Hemorrhage in Patients With Nonvalvular Atrial Fibrillation: A Subanalysis of the J‐RHYTHM Registry
by: Eitaro Kodani, et al.
Published: (2016-09-01)

Minimally Interrupted Non-Vitamin K Antagonist Oral Anticoagulants vs. Bridging Therapy and Uninterrupted Vitamin K Antagonists During Atrial Fibrillation Ablation: A Retrospective Single-Center Study
by: Lihong Tang, et al.
Published: (2020-06-01)

Prevalence, Epidemiological Characteristics, and Pharmacotherapy of Coronary Artery Disease among Patients with Atrial Fibrillation: Data from Jo-Fib Study
by: Hanna K. Al-Makhamreh, et al.
Published: (2021-06-01)

Elevated plasma Ninjurin-1 levels in atrial fibrillation is associated with atrial remodeling and thromboembolic risk
by: Chen Fang, et al.
Published: (2022-04-01)

How to manage anticoagulation for cancer-associated thrombosis and atrial fibrillation in cancer
by: Antonella Tufano, et al.
Published: (2024-06-01)

Extracellular Vesicles and Thrombogenicity in Atrial Fibrillation
by: Alexander E. Berezin, et al.
Published: (2022-02-01)

Effect of the Alterations in Contractility and Morphology Produced by Atrial Fibrillation on the Thrombosis Potential of the Left Atrial Appendage
by: Danila Vella, et al.
Published: (2021-02-01)

Atrial Fibrillation after Cardiac Surgery: Where are we now?
by: Dimpi Patel, et al.
Published: (2008-11-01)

Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true
by: Yu. A. Bunin, et al.
Published: (2016-09-01)